The Top Line · Fierce Life Sciences
How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)
·15 min·1 clip
Merum anticipates four major drug trial readouts that could lead to regulatory approvals in just 18 months.
As heard by us
A measured rare-disease M&A briefing with a clear pipeline cadence and sponsor-backed framing.
The episode centers on Ajay Narasimha's case for why Merum's Blue Jay Therapeutics acquisition fits a rare-disease business that is already built for launch.
Why you'd press play
You want a calm read on Merum's rare-disease deal and the pipeline behind it.
Listen to the show on